ASCO 2019 | Melanoma: targeted vs. sequencing immunotherapy
Both sequencing and targeted immunotherapy are good options for melanoma. Paolo Ascierto, MD, of the National Tumor Institute, Milan, Italy, gives his perspectives on both approaches. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Get great new content delivered to your inboxSign up